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Doubling time methodand spectral karyotyping (SKY) of cancer cells and tumorigenic models have shown this progression
involves three major types of genome rearrangements: ordered small step-wise changes, more dramatic
“punctuated evolution” (chromoplexy), and large catastrophic steps (chromothripsis) which all occur in
random combinations to generate near inﬁnite numbers of stochastically rearranged metastatic cancer
cell genomes. This paper describes a series of mouse cell lines developed sequentially to mimic this type
of progression. This starts with the new GhrasT-NIH/Swiss cell line that was produced from the NIH/3T3
cell line that had been transformed by transfection with HRAS oncogene DNA from the T24 human
bladder carcinoma. These GhrasT-NIH/Swiss cells were injected s.c. into NIH/Swiss mice to produce
primary tumors from which one was used to establish the T1-A cell line. T1-A cells injected i.v. into the
tail vein of a NIH/Swiss mouse produced a local metastatic tumor near the base of the tail fromwhich the
T2-A cell line was established. T2-A cells injected i.v. into the tail vein of a nude NIH/Swiss mouse
produced metastases in the liver and one lung from which the T3-HA (H¼hepatic) and T3-PA
(P¼pulmonary) cell lines were developed, respectively. T3-HA cells injected i.v. into a nude mouse
produced a metastasis in the lung from which the T4-PA cell line was established. PCR analysis indicated
the human T24 HRAS oncogene was carried along with each in vitro/in vivo transfer step and found in the
T2-A and T4-PA cell lines. Light photomicrographs indicate that all transformed cells are morphologically
similar. GhrasT-NIH/Swiss cells injected s.c. produced tumors in 4% of NIH/Swiss mice in 6–10 weeks; T1-
A cells injected s.c. produced tumors in 100% of NIH/Swiss mice in 7–10 days. T1-A, T-2A, T3-HA and T4-
PA cells when injected i.v. into the tail produced local metastasis in non-nude or nude NIH/Swiss mice.
T4-PA cells were more widely metastatic than T3-HA cells when injected i.v. into nude mice. Evaluation
of the injected mice indicated a general increase in metastatic potential of each cell line in the pro-
gression as compared to the GhrasT-NIH/3T3 transformed cells. A new photomicrographic technique to
follow growth rates within six preselected 22 mm2 grids per plate is described. Average doubling times
of the transformed cells GhrasT-NIH/3T3 (17 h), T1A (17.5 h), T2A (15.5 h), T3-HA (17.5 h) and T4-PA
(18.5 h) (average 17.2 h) were signiﬁcantly faster (P¼0.006) than NIH Swiss primary embryonic cells and
NIH/3T3 cells (22 h each). This cell series is currently used in this lab for studies of cancer cell inhibitors,
mitochondrial biogenesis and gene expression and is available for further study by other investigators for
intra- and inter-laboratory comparisons of WGS, transcriptome sequencing, SKY and other analyses. The
genome rearrangements in these cells together with their phenotypic properties may help provide more
insights into how one tumorigenic progression occurred to produce the various cell lines that led to the
highly metastatic T4-PA cell line.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
It is well established that human cancers develop in a multistep
sequence with environmental inﬂuences including chemical,
physical, and viral agents being major etiological contributors
[22,42]. Numerous transitions occur in a “tumorigenic progres-
sion” as cells change from “normal” to “immortalized” [4,9,35] to
“transformed” and ﬁnally to the “metastatic state” [2,3,16,18,33].
The classical textbook view of a gradual accumulation of genomic
alterations in this progression has been enlightened using next
generation whole genome sequencing (WGS) and spectral kar-
yotyping (SKY) with the recent description of stochastic cancer
genome fragment rearrangements [2,9,18,33]. Several types and
subtypes of stress-induced genome chaotic genome rearrange-
ments have been thoroughly documented in some excellent in
vitro models [2,9,18,33].
Three major types of genome rearrangements have been
characterized. (1) Progressive minor genome changes affecting one
or several cancer driving genes. This ﬁrst type deﬁned as “step-
wise genome evolution” produces heterogeneous stable dominant
clonal chromosome aberrations (CCAs) along with low frequency
non-clonal chromosomal aberrations (NCCAs) within the tumor
cell population. (2) Chromoplexy, deﬁned as a frequent punctuated
genome evolution involving fragmentation and simultaneous
stochastic rejoining at multiple distant genomic regions all at once
[2,33]. This second type also termed “punctuated phase” is char-
acterized by elevated numbers of NCCAs and transitional CCAs. (3)
Chromothripsis which involves a sudden catastrophic fragmenta-
tion and rejoining of DNA either on a limited number of chro-
mosomes [2,9,18,33] or over wider ranges among several chro-
mosomes [18].
These ﬁrst two types were carefully documented in an im-
mortalization study using SKY analysis to evaluate well-characterizedpassage levels of a human ﬁbroblast cell line generated from Li-
Fraumeni syndrome patients [9]. This study also documented that
mouse and human knock-out cell lines with compromised genome
stability when stressed by introducing onco-proteins or carcinogens
produced stochastic karyotypic patterns. This clearly indicated the
CCAs/NCCAs patterns described above. From these and other studies
Heng proposed a model of how genome fragmentation followed by
stochastic rejoining produces a variety of chaotic karyotypes. Sub-
sequent genomic evolution provides inﬁnite genetic combinations
and the interplay between transitional CCAs and NCCAs is the key
driving force in cancer progression leading to near inﬁnite eu-
karyotic–phenotypic and genetic network changes in each cell’s
evolution to metastasis [9,18,33].
Other more recent work using WGS has demonstrated how the
third type occurs as one rapid catastrophic “chromothripsis” event
that shatters DNA into pieces leading to hundreds of genomic re-
arrangements, a phenomenon shown to have occurred in two to
three percent of all cancers [34]. These cells may become dominant
in a heterogeneous tumor population allowing cancer to form re-
latively quickly in these cases as they then continue to progress
through a multistage process. Chromothripsis has been implicated
in some of the early genomic rearrangements as seen in the se-
quenced genome of the universally employed human cancer model
HeLa cell line [1,14]. The predominant hyper-triploid proﬁle of eight
HeLa cell strains is consistent with published karyotypes of various
HeLa strains, suggesting that they became mostly hyper-triploid
illustrating a chromothripsis either during tumorigenesis or early in
the establishment of the HeLa cell line [1]. This ﬁnding illustrates
why transformed cells in culture for shorter periods than HeLa's 68
years should remain relatively stable once established from tumors
with inherent malignant and metastatic characteristics. This afﬁrms
the usefulness of model cancer cell lines in evaluating cancer tumor
cell treatments between various laboratories.
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event in the progression of the used HeLa cell, recent studies with
HeLa cell transfectants show the “step-wise” type progression
occurs during plasmid transfection [33]. These cells were trans-
fected with a plasmid containing CHI3L1 that encodes the secreted
chitinase 3-like 1 protein (This protein has been shown to enhance
the cancer phenotype of 293 cells, i.e., decreased doubling time
and increased anchorage-independent growth in soft agar [11].)
Long-term treatment of HeLa cells with temozolomide (TMZ) has
shown a similar progression. In contrast, studies with transformed
human embryonic kidney cells (HEK293 cells) transfected with
either the empty pcDNA3.1 vector or the pcDNA3.1_CHI3L1 vector
or treated with TMZ demonstrated more pronounced chaotic
chromosomal rearrangements, consistent with chromoplexy, that
coincided with karyotype-phenotype correlations. This illustrates
how the same transgene or chemical agent stressors can have
different effects on different cell types with different genomes and
genetic networks [33].
These recent studies have shown that the majority of cancer
cells progressing through these phenotypic transitions and have
undergone genomic fragmentation and stochastic rearrange-
ments: (1) do not only occur in restricted regions; (2) that the
several types do not always arise in identical chronological events
reﬂecting how each cancer cell has its unique progression and
outcome; (3) that each type of fragmentation produced may de-
pend on the context of the cell's particular genome prior to gen-
ome fragmentation and (4) that each stable outcome may be a
transition on the road for short-term survival or long-term evo-
lution toward more metastatic (and often drug resistant) growth
[2,18,33].
Thus the progressions of these multistep processes involve:
(1) small gradual steps that allow cells to survive better; (2) mid
sized punctuated evolution (chromoplexy) steps and (3) large
catastrophic steps (chromothripsis) that may make survivabilityFig. 1. Graphical abstract of the source, derivation anmore challenging if numerous critical survival genes are suddenly
compromised. Since these types do not always occur in identical
progressive orders their occurrence clearly depends on the gen-
ome context of the cell type “(a number and structure of chro-
mosomes and their nucleus topology)” that “drives the genetic
network (gene content, RNA and protein interaction), the tran-
scriptome, gene isoform expression, protein abundance, sub-
cellular localization, and protein–protein interactions…” [33, p.
63], during metastatic progression of each unique cancer [2,18,33].
More recent results from studies of tumor cells in vivo have
clearly demonstrated the importance of micro-environmental cell-
to-cell interactions, as well as paracrine and endocrine inﬂuences,
on the ways tumor cells and their progeny change over time and
space [6,32,19]. Cancer stem cells and their role in the initiation
events leading to cancer cell transformation and their self-re-
newing characteristics have shed light on the tumorigenic process
and highlighted problems associated with effective killing of both
non-cancer stem cells and cancer stem cells [12,19,31,40].
The human transforming HRAS gene cloned from either the
T24 or EJ bladder carcinoma cell lines is well known to transform
the immortal NIH/3T3 cell line, established by Jainchil et al. [10] in
oncogene discoveries reviewed by Malumbres and Barbacid [21].
The ras oncogenes (HRAS, KRAS and NRAS) are known to exploit
their signaling pathways to help drive tumorigenesis in a large
number of cancer types [26]. The transforming DNA from the EJ
human bladder carcinoma cell line (EJ-Ha-ras) was identiﬁed as
the activated HRAS oncogene. The EJ-6-2-Bam-6a cell line (ATTC
CRL-1888) was established by transfection of this activated HRAS
oncogene into immortalized NIH/3T3 cells. This transfected cell
line, paired with the untransfected NIH/3T3 cell line, is being used
globally to evaluate the effects of HRAS transformation in the tu-
morigenic process. They are being used for many recent ap-
proaches to understand the control of cell death in the malignant
cell [13], and to evaluate the mechanisms cancer cells utilize tod growth characteristics of each cell or cell line.
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devise ways to target cancer cells with speciﬁc decorated nano-
particles to image and ultimately kill cancer cells when the par-
ticles are attached to tumor-speciﬁc toxins [24].
To better understand the importance of transformations and
tumor progression changes on disease status, prognosis, and
treatment, universally available tumor model systems will con-
tinue to help establish a testable dataset in the application of
modern molecular techniques. These model systems can be com-
bined with bioinformatic analyses and applied to large datasets of
clinical genomics that are being assembled around the world.
Model systems may even be useful to help address quality-control
issues relevant to development of universal standards for intra-
and inter-laboratory comparisons of reproducibility and sample
tracking within large world wide efforts to standardize clinical
genomic data [23].
The aim of the present study was to establish cell lines from a
new HRAS transfection system using T24 human bladder carci-
noma DNA and to establish cells derived from it that represent
various stages in one tumor progression that includes several
additional metastatic cell types (Fig. 1, graphical abstract). The
advantage of this approach is that all transformed cells in the
series are derived from a common transfected parent population,
namely, the GhrasT-NIH/3T3 cell line used in this study. This cell
line was generated by transfection with DNA from the T24 human
bladder carcinoma. The design to intentionally expose different
metastatic cells to in vivo micro-environmental effects as they
adapt to multiple targets was accomplished by alternating be-
tween in vitro and in vivo growth in the development of this series.
The ﬁrst cell line in the series (T1-A) was cultured from a primary
tumor in a NIH/Swiss mouse injected s.c. with the GhrasT-NIH/3T3
cells. The second cell line (T-2A) was cultured from a subsequent
secondary local metastasis in a NIH/Swiss mouse injected i.v. with
T1-A cells. The third cell line (T3-HA) was cultured from a tertiary
liver metastatic tumor in a nude NIH/Swiss mouse injected i.v.
with T2-A cells. The fourth cell line (T4-PA) was cultured from a
quaternary metastatic tumor in a nude NIH/Swiss mouse injected
i.v. with T3-HA cells. These T4-PA cells caused wide spread me-
tastases following i.v. injection into nude mice. The tumorigenic
growth and morphological properties of these T24 bladder carci-
noma derived cell lines described here appear to be quite different
from those derived from the human EJ-6-2-Bam-6a cell line
transfection system. A new photomicrographic method was uti-
lized here to measure the in vitro growth rates of these cell lines as
they replicate in speciﬁc 22 mm2 areas on gridded plates. This
new series of cells has proven useful in studies of growth inhibi-
tion testing of various compounds, and medicinal plant extracts
[38], as well as mitochondrial biogenesis, and gene expression
studies in this lab (D.B. Ray, pers. comm.) and should be useful for
further study in other laboratories. These lines offer the opportu-
nity to evaluate single cell variations within and among a variety
of cell lines derived from a common tumorigenic event(s) This
may give insights into potential stochastic chromosomal re-
arrangements, eukaryotic–phenotypic and genetic network chan-
ges that have occurred within the progression leading to the
highly metastatic T4-PA cells.2. Methods
2.1. Animals
Breeding pairs of NIH Swiss and NFS/NCr mice were obtained
from L. Watson at NIH or the Jackson Labs and bred as outbred or
inbred strains, respectively, as described by the Jackson Lab pro-
tocols. All mice at the Oral Roberts University Medical School werehoused in the animal facility of the Biomedical Research Center,
fully accredited by the American Association for the Accreditation
of Laboratory Animal Care, and cared for in accordance with the
guidelines of the National Research Council for the care and use of
laboratory animals under the supervision of a licensed veterinar-
ian. All mice at Grove City College were cared for with the same
animal studies guidelines for animal use as approved by the Grove
City College Institutional Review Board, which served as the ani-
mal oversight committee at the time. Nude mice (Nu/Nu) were
obtained from Jackson Labs, Farmington, Connecticut (common
name: nu/nu; strain name: NU/J; stock number: 002019) or ob-
tained from a breeding pair (Nuþ/Nu) offspring. These are from
a spontaneous mutation athymic (nude) inbred mice on an N:NIH
(s) background homozygous for nude marker, Nu/N and im-
muno-compromised. The two main defects of mice homozygous
for the nude spontaneous mutation (Foxn1nu, formerly Hfh11nu) are
abnormal hair growth and defective development of the thymic
epithelium. The Jackson Laboratory imported the nude mutation
from the NIH on an outbred stock. As of 2008, the strain has been
inbred for at least 100 generations. The studies reported here with
these mice were completed between 1995 and 2000. NFS/NCr
inbred mice were obtained from the Jackson Lab and maintained
as an inbred colony. They have a very low incidence of sponta-
neous lymphoma.
2.2. Source, derivation and growth characteristics of each cell or cell
line (Fig. 1)
All cells and cell lines were grown at 37 °C in 5% CO2/95% air in
Dulbecco's modiﬁed Eagle's medium (DMEM) (catalogue #12320-
032, GIBCO, Grand Island, NY) supplemented with extra added D-
(þ) glucose (catalogue #G-5400, Sigma Chemical Company, St.
Louis, MO) (4.5 g/L), 10% fetal calf serum (catalogue #SH30070.02,
Hyclone Laboratories, Logan, Utah), and 20 Units/ml penicillin, and
20 μg/ml streptomycin (catalogue #15140-122, Sigma Chemical
Company). Extra glucose was included to insure a rich glucose
source for rapidly growing tumor cells that are known to utilize
aerobic glycolysis as a major source of energy and glycolytic in-
termediates [39,41].
2.2.1. Normal primary NIH Swiss embryonic cell cultures (mortal)
These cells were prepared from 17 to 19 days old NIH Swiss
mouse embryos by ﬁne mincing of whole embryos with scissors by
the methods employed by Todaro and Green [37]. These minces were
used for growing primary normal cell cultures and for DNA extrac-
tions as needed. The tissue was disaggregated with 0.25% trypsin-
EDTA (catalogue #25200-056, GIBCO), cells were collected by cen-
trifugation, resuspended in saline (0.9% NaCl) (catalogue #R5200-01,
B. Braum Medical, Inc., Irvine CA) and when useful, viable cells were
identiﬁed by Trypan blue exclusion (catalogue #15250061, GIBCO),
and counted in a hemocytometer. Cells were plated at 4.3105 cells/
60 mm diameter dishes and grown in D-MEM supplemented as
described above. Cultures were expanded and subcultures were
frozen in Recovery Cell Culture Freezing Media (catalogue #12648-
010, GIBCO) and stored in liquid nitrogen tanks as stocks.
2.2.2. NIH/3T3 cells (immortal)
The “immortal” NIH/3T3 cells (ATCCs CRL1658™) cells were
purchased from the American Type Culture Collection (Manassas,
VA) at passage #126. These cells were originally developed [10] by
growing primary embryonic cells, prepared as described above
[37], using a rigid transfer schedule (every 3–4 days). These cells
were non-tumorigenic when 1106 cells were injected s.c. into 23
NFS/Ncr inbred mice or 105 outbred NIH Swiss mice (Table 1).
Cultures were expanded and subcultures were frozen and stored
in liquid nitrogen as stocks.
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(transformed)
The HRAS oncogene-transfected NIH/3T3 cells were obtained
from Dr. David A. Goldthwait at the Department of Biochemistry,
Case Western Reserve University in Cleveland, Ohio and desig-
nated as G-hrasT-NIH/3T3 cells. (G denotes their source from the
Goldthwait Lab, T denotes their transformed cell type.) The
Goldthwait cells were isolated from a focus of transformed cells
following transfection with DNA from the T24 Human bladder
carcinoma. This cell line contains the Harvey-ras oncogene iso-
lated from the T24 human bladder carcinoma that has been shown
to have a glycine to valine substitution at the twelfth amino acid
residue of the T24 oncogene encoded p21 protein [28]. The pT24-
C3 plasmid (ATCC 41000™) used for the transfection of the NIH/
3T3 cell line by Dr. Goldthwait is a pBR322 derived plasmid con-
taining the 6.6 Kilo base pair BamHI fragment of the T24-Ha-ras1
oncogene and is carried in E. coli C-600 strain (Goldthwait, D.A.,
unpublished results). GhrasT-NIH/3T3 cultures were expanded and
subcultures were frozen and stored in liquid nitrogen as stocks.
2.2.4. Highly tumorigenic ras T1-A cells
Following s.c. injection of 1106 GhrasT-NIH/3T3 cells/mouse
into hindquarters of 104 outbred NIH Swiss mice, four mice
formed single primary tumors within 6 to 10 weeks at their in-
jection sites (Table 1). Two of these tumors from separate mice
were excised, minced and cultured as described above giving rise
to the T1-A and T1-C cell lines. The T1-A and T1-C cells were sub-
cultured several times and stocks were saved frozen in liquid ni-
trogen. Additionally, to assess the tumorigenic potential of the T1-
A and T1-C cell lines, 20 and 14 outbred NIH Swiss mice were
injected s.c. in the hindquarters with T1-A (1106 cells/mouse) or
T1-C (1106 cells/mouse) cells respectively and observed for tu-
mors at the injection sites
2.2.5. T2-A cell line from local metastasis in NIH Swiss mouse
To seek a metastatic lesion derived from these T1-A cells, 1106
cells were injected into the tail veins of several NIH Swiss mice. A
tumor was located in the rump near the base of the tail of one mouse
within 13 days of tail vein injection. This local metastasis was excised,
minced and cultured, establishing the T2-A cell line. These cells were
expanded and subcultures were frozen and stored in liquid nitrogen.
Thus, this T2-A cell line was derived from a fast growing local me-
tastasis close to but not at the site of injection in the tail.
2.2.6. T3-HA and T3-PA metastatic cells from distant liver lung me-
tastasis in a nude NIH Swiss mouse
In attempts to acquire a highly metastatic cell line in this series,
1106 T2-A cells were injected into the tail veins of four immune-Table 1
Primary tumor occurances in mice injected with various cell linesa.
Cell line Recipient mouse Injection site
NIH/3T3 NFS/NCr (inbred) Hind quarter
NIH/3T3 NIH Swiss (outbread) Hind quarter
GhrasT-NIH/3T3 NFS/NCr (inbred) Hind quarter
GhrasT-NIH/3T3 NIH Swiss (outbread) Hind quarter
GhrasT-NIH/3T3 nude NIH/Swiss Hind quarter
T1-A NFS/NCr (inbred) Hind quarter
T1-A NIH Swiss (outbread) Hind quarter
T1-A NIH Swiss (outbread) Tail vein, i.v.
T1-C NFS/NCr (inbred) Hind quarter
T1-C NIH Swiss (outbread) Hind quarter
a 1.0106 cells injected per mouse.
b Not available.
c Not determined.
d These 4 tumors were local metastases in the base of the tails and the T-2A cell lincompromised nude NIH/Swiss mice. One mouse was sacriﬁced
periodically and examined for evidence of tumors. After 3.5 weeks
a mouse was sacriﬁced which contained a metastatic lesion in
both the liver and a lung that were excised, minced, cultured and
designated T3-HA (H¼hepatic) and T3-PA (P¼ pulmonary) cells,
respectively. These cells were expanded in culture and stored in
liquid nitrogen.
2.2.7. T4-PA metastatic cells from distant lung metastasis in nude
NIH Swiss mouse
To determine if the T3-HA cells derived from the ﬁrst distant
metastatic lesion would generate second metastatic lesions in the
liver, 0.7106 T3-HA cells were injected into the tail veins of four
NIH/Swiss nude mice. After 4 weeks, a metastatic lesion was found
in the lung of one mouse. The lesion was excised, minced, cultured
and the cells were designated T4-PA (P¼pulmonary) cells. These
cells were expanded and stored in liquid nitrogen.
2.3. DNA extraction
Total DNA was isolated from tissue or cell pellets by a mod-
iﬁcation of the methods of Davis et al. [5].
2.4. Human ras oncogene polymerase chain reaction (PCR) analysis
The presence of this human oncogene in the ras transfected
G-hrasT-NIH/Swiss and its descendent cell lines was conﬁrmed by
PCR ampliﬁcation with the use of human speciﬁc H-ras primers.
Mouse speciﬁc primers were used for a control PCR. Primers were
designed by methods similar to those of [20] as published pre-
viously [27, p. 422].
Primers designed:
HN, MN¼human or mouse primer that becomes the non-
template strand of the DNA
HT, MT¼human or mouse primer that becomes the template
strand of the DNA
Human ras primers: designed and named from GenBank: J00277;
formerly V00574 [29,36]. These human speciﬁc primers will am-
plify the same region in either the normal human proto-oncogene
or the human T24-Ha-ras1 oncogene.
HN-3630 5′-CTG-TCT-TCA-ACA-TCC-CAA-ATG-CC-3′
(Note: although this C should be G to match the published se-
quence, V00574, the PCR was successful.)
HT-4781 5′-AGT-GTG-GTA-TTC-CCT-GGA-CAA-AAG-G-3′
Mouse ras primers: designed and named from GenBank: Z50013.1
[25]. These mouse speciﬁc primers will amplify a region in the
normal mouse proto-oncogene.
MN-1121 5′-GGC-CTT-AGT-TCT-TCT-TGT-CC-3′# Of tumors per # of mice injected % Tumors Time period
0/23 0
0/105 0
14/45 31 6–10 weeks
4/104 4 6–10 weeks
2/2 100 N.A.b
N.D.c
20/20 100 7–10 days
4/4 100 13 daysd
N.D.c
13/14 93 7–10 days
e was established from one of them.
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PCR was performed as described previously [27, p. 422]. DNA
was puriﬁed as described above and purity and concentration
were analyzed via UV/VIS spectrophotometry. Each 50 μL reaction
contained 10 mM Tis–HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2,
200 μM each of dATP, dCTP, dGTP, dTTP, 0.2 μM primer one (for-
ward) and 0.2 μM primer two (reverse), 0.5 μg DNA, 1.25 Units of
Taq-Gold polymerase (Applied Biosystems, Grand Island, NY). The
thermocycler program included 10 min at 95 °C; a 40-cycle repeat
of: 1 min at 94 °C, 1 min at 55 °C, and 1 min at 72 °C, and followed
by a polishing time of 6 min at 72 °C. Agarose slab gel electro-
phoresis was performed and EtBr stained gels were photographed
by a Gel Doc XR from BIO-RAD using Quantity Ones software
(BIO-RAD, Hercules, CA) to analyze the gels and assign a speciﬁc
base pair value to each DNA fragment based on the sizing
standards.
2.5. Determination of cell growth rates
Cells were plated in the DMEM described above in 60 mm
diameter dishes with 22 mm2 square grids (Corning cat
#430196, Corning, NY). Six predetermined squares were pre-
marked with marking pen on each dish prior to use. The squares
were scattered in such a way that each 22 mm2 square area
would be representative of the entire plate. Photographs were
taken daily when cells reached 20–40% conﬂuency (day 0) with an
Olympus DP12 inverted Microscope (Olympus America, Inc., Mel-
ville, NY) with a Digital Camera System at 100 in the center of
each selected 22 mm2 square. Cell counts for each square were
determined from the photomicrographs and the average for the
6 squares was determined for each day. Results for each day were
normalized to fold increase relative to day 0. Statistical sig-
niﬁcance was determined via T-test.3. Results and discussion
3.1. Normal NIH Swiss embryonic cells
The normal primary NIH Swiss embryonic cells used to estab-
lish the other cell lines in this tumorigenic progression model
were obtained from 17 to 19 days old NIH Swiss mouse embryos
[37]. They are anchorage dependent, contact inhibited, and mortal,
surviving about 30 cell divisions before they become senescent as
typical for most diploid cell cultures [17,37].
3.2. NIH/3T3 cell line
The NIH/3T3 cell line was derived from NIH Swiss embryonic
cells that have escaped this senescent “crisis” to become, immortal
and contact inhibited. Although not transformed, they already
have obtained properties associated with transformed cells [17].
They were not tumorigenic (Table 1) in the inbred NFS/NCr mice (0
tumors in 23 mice injected) or in the outbred NIH Swiss strain of
mice (0 tumors in 105 mice injected). Each mouse was injected
with 1106 cells s.c. This negative result with NFS/NCr mice was
the same as the results of Bernstein and Weinberg [3]. Variable
tumorigenic and metastatic capabilities of NIH/3T3 cells have been
reported. NIH/3T3 cells produce tumors in BALB-c nude mice [8].
These cells grow rapidly and when transferred at 4.3105 cells/
50 mm diameter culture dish they form conﬂuent monolayers
within 2–3 days. Differences in NIH/3T3 cell stocks, passage
numbers, site of tumor cell inoculation and cell number inocula-
tions may be responsible for different outcomes. In addition, in
some transfection experiments, untransfected control NIH/3T3
cells have been shown to undergo “spontaneous transformation”,thought to be more frequent when these cells are maintained at
conﬂuency for extended times prior to subculturing [30,8].
3.3. GhrasT-NIH/3T3
Transfecting the Harvey-ras oncogene into the NIH/3T3 cell line
is well known to transform it into a tumorigenic cell type [3]. To
conﬁrm this, the tumorigenic capability of the ras-oncogene
transfected NIH/3T3 cells (GhrasT-NIH/3T3) was tested for tumor
formation in normal mice. Injection of 1106 cells s.c. into the
rear ﬂank of mice produced (20–30 mm diameter) primary tumors
in 14 of 45 (31%) of inbred NFS/NCr mice and in 4 of 104 (4%) of
outbred NIH/Swiss mice all within 6–10 weeks (Table 1). This was
different than the ﬁndings of Bernstein and Weinberg who re-
ported 100% tumor formation when injecting equivalent amounts
of the EJ-6-2-Bam-6a cells (ATCC-1888TM) into the NFS/NCr mouse
strain.
These differences may indicate that the immortalized NIH/3T3
cells transfected with the plasmid containing the T24 DNA that
yielded the GhrasT-NIH/3T3 cells may have undergone a more
severe chaotic genomic rearrangement during transfection than
the NIH/3T3 cells transfected with the plasmid containing the EJ-
6-2DNA that yielded EJ-6-2Bam-6a cell line. Since several studies
have indicated signiﬁcant phenotypic changes can occur with
transfection with empty vectors into several cell lines [33], the role
of different vectors used to produce these two cell lines and the
stochastic events that occurred during each transfection process
may account for some of the phenotypic differences. But as
pointed out [33], it is difﬁcult “…to discriminate which phenotype
changes are caused by changes in gene expression and which are
due to stress-induced chromosomal arrangements?”. Future
comparisons of the chromosomal arrangements and tran-
scriptomes of these two ras transformed NIH/3T3 cell lines may
help shed light on their phenotypic differences.
Consistent with the results of Bernstein and Weinstein's EJ-6-2-
Bam-6a cells' results [3], injection of these GhrasT-NIH/3T3 cells s.
c. into the rear ﬂank of two nude NIH Swiss mice produced tumors
at the site of injection in each mouse (Table 1). Other studies [8]
using a third ras oncogene transfected NIH/3T3 cell line, A51 [7],
injected s.c. into BALB/c nude mice generated primary tumors in
15–25 days. Some of the differences between the ﬁndings with the
GhrasT-NIH/3T3 cells and the EJ-6-2-Bam-6a cells could be related
to the number of transfections used to produce these two cell lines
or the speciﬁc site where the ras oncogene BamHI fragment in-
serted into the two different NIH/3T3 mouse cell genomes during
each transfection process. In summary, GhrasT-NIH/3T3 cells are
transformed, immortal and tumorigenic (Table 1).
3.4. Highly tumorigenic ras T1-A cell line
Two primary tumors selected from the four observed tumors
produced at the cell's injection sites following s.c. injection of
GhrasT-NIH/3T3 cells into 104 outbred NIH Swiss mice were ex-
cised, minced and cultured as described above giving rise to the
T1-A and T1-C cell lines. Their tumorigenic capability was tested
by s. c. injection into the hindquarters of NIH Swiss mice. T1-A
cells produced 20 tumors in 20 mice (100%) and T1-C produced 13
tumors in 14 mice (93%) all within 7–10 days (Table 1). This in-
dicated the T1-A and T1-C cell lines were signiﬁcantly more ag-
gressive at producing tumors than the GhrasT-NIH/3T3 cells that
required 6 to 10 weeks for tumor growth. All but one of the 34
mice injected developed a primary tumor and the tumors devel-
oped 4–10 times faster than the ras-transformed GhrasT-NIH/3T3
cells did in outbred NIH/Swiss mice (Table 1). Thus, the inherent
tumorigenic capabilities of the T1-A and T-1C cells have each in-
creased in NIH/Swiss mice as this GhrasT-NIH/3T3 tumor line was
Table 2
Metastatic tumor occurrence in mice after tail vein injection with various cell lines.
Cell line (passage #s) t # of mice
injected Outcomes
Recipient # Of mice
injected
Outcomes
T1-A (n.a.)a NIH Swiss (outbred) 4 Four had a local metastatic tumor in rumps near tails after 13 days, none with obvious
internal metastatic lesions.
The T2-A cell line was established from one of these local metastases.
T2-A (7, 9) Nude NIH/Swiss 10 Four died within 21-27 days; most of the other 6 all had local mets in rump near tail; two
others developed distant metastatic tumors in the liver , lung, pericardium, or throat.
The T3-HA cell line was established from one met in the liver.
T3-HA (2, 3) Nude NIH Swiss
(inbred)
3 One died after 58 days, one had no mets after 34 days and one had metastatic tumors in
the liver and lung after 27 days.
T4-PA cell line was established from this lung.
T4-PA ( 2, 3) Nude NIH Swiss
(inbred)
4 One died after 29 days, one had metastases near the liver, lungs and in the neck region
after 24 days; one had tumor at base of tail, metastases in intestines and near spleen after
30 days; one had met on right hind leg and lower groin area after 31 days. Cells cultured
from these lesions failed to thrive.
a n.a., not available.
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tumorigenic phenotypes of these two cell lines originating from
tumors in similar in vivo microenvironments in separate mice is
consistent with the concept they each may contain some transi-
tional or dominant CCAs they acquired from the GhrasT-T-NIH/3T3
cells that gave them similar selective growth advantages. WGS and
SKY analysis of these cell lines and tumors and downstream cell
lines generated from them could test this possibility. These ana-
lyses may help shed some light on what chromosomal/gene ar-
rangements may give these cells selective tumorigenic advantages.
3.5. T2-A cell line from local metastasis in NIH Swiss mouse
T1-A cells (1106/mouse) were injected i.v. into the tail veins
of NIH Swiss mice (Table 2). A local metastatic tumor developed in
the rump near the base of the tail of one mouse within 13 days,
again illustrating a more rapid tumorigenic process than the ori-
ginal GhrasT-NIH/3T3 cells. No distant metastatic lesions were
found in the mice injected. Cells cultured from this local metastatic
tumor were designated T2-A cells. Therefore, this T2-A cell line
was derived from a fast growing local metastasis close to, but not
at the site of injection in the tail.
3.6. T3-HA metastatic cells from distant liver metastasis in nude NIH
Swiss mouse
T2-A cells (1106/mouse) were injected into the tail veins of
four immune compromised nude NIH/Swiss mice. Each week one
mouse was dissected to determine the existence of metastatic
lesions. At 3.5 weeks, a mouse was sacriﬁced and observed to
contain a metastatic lesion in both the liver and a lung. Both tu-
mors were excised, minced, cultured and designated T3-HA
(H¼hepatic) and T3-PA (P¼pulmonary) cells, respectively.
Therefore, these cell lines were derived from the local metastatic
type T2-A cells migrating from the tail vein injection site of the
nude mouse to the liver (T3-HA) or to the lung (T3-PA) to form
distant metastatic lesions. This showed that the T2-A cells were
capable of metastasizing to distant locations in the nude NIH/
Swiss mice. This illustrated the ﬁrst distant metastatic property by
the T2-A cells and the establishment of the T3-HA and T3-PA
metastasized cell lines in this tumor progression model. WGC and
SKY analysis of T2-A and these two metastatic cell lines generated
in vivo in a single mouse might indicate which chromosomal ar-
rangements were common or not between populations of each cell
line. These analyses would provide interesting aspects of chro-
mosomal arrangements related to metastatic potential of T2-Acells in vivo giving rise to two cell lines, each derived from the T2-
A cell line, that grew simultaneously in separate liver or lung
microenvironments in the same mouse.
3.7. T4-PA metastatic cells from distant lung metastasis in nude NIH
Swiss mouse
To determine if the T3-HA (liver derived) cells from the ﬁrst
distant metastatic liver lesion would go to the liver and generate
second metastatic lesions in the liver, 0.7106 T3-HA cells were
injected into the tail veins of four NIH/Swiss nude mice. [T3-PA
(lung derived) cells were not tested.] Each week one mouse was
dissected to determine metastatic lesions. After 4 weeks, a meta-
static lesion occurred in the lung of one mouse. The lesion was
excised, minced, cultured and designated T4-PA (P¼pulmonary)
cell line. This T4-PA cell line was derived from a tumor that had
formed from hepatic derived metastatic cells migrating from the
tail vein injection site to the lung leaving the circulation to form a
metastatic lesion, thereby showing that the T3-HA cells were
capable of metastasizing to a distant location other than the liver
in the nude NIH/Swiss mice. This illustrated the distant metastatic
property of the T3-HA cells and the establishment of the T4-PA
metastasized cell lines in this tumor progression model.
3.8. Overall comparisons of tumorigenic and metastatic properties
Further studies were undertaken to determine if the T3-HA
cells and T4-PA cells metastasize to speciﬁc sites. After the T1-A
and T-1C cell lines were discovered to rapidly produce primary
tumors when injected s.c. in immune-competent NIH Swiss
outbred mice (Table 1). They were then injected in the tail veins (i.
v.) of these NIH/Swiss mice to search for metastatic lesions. These
produced only local metastatic lesions near the tail (Table 2). The
T2-A cell line was derived from one of these local metastatic le-
sions. To enhance the opportunity to produce a metastatic lesion,
T2-A cells were injected in the tail vein of a group of partially
immune-compromised nude NIH Swiss mice (Table 2). This ap-
proach with these T2-A cells, derived from a single local metastasis
in a NIH/Swiss mouse, did produce distant metastatic liver, lung,
pericardium or throat lesions in nude mice. Cells from a liver le-
sion were used to establish the T3-HA cell line (and cells from the
lung of the same mouse were used to establish the T-3-PA cell
line). Thus, this new distant metastatic T3-HA cell line in a nude
mouse was derived serially from cells cultured from a local me-
tastatic lesion in a NIH/Swiss mouse. These outcomes (Table 2)
indicated that the lung and liver are the most common sites for
Fig. 2. Photomicrographs of normal and transformed cells. (A and B) NIH Swiss
embryonic 100 , lower and higher cell densities, respectively. (C and D) NIH/3T3
100 , lower and higher cell densities, respectively. (E and F) GhrasT-NIH/3T3
100 , lower and higher cell densities, respectively. (G and H) T1-A 100 , lower
and higher cell densities, respectively. (I and J) T2-A 100 , lower and higher cell
densities, respectively. (K and L) T3-HA 100 , lower and higher cell densities,
respectively. (M and N) T4-PA 100 , lower and higher cell densities, respectively.
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the T2-A or T3-HA cells. (As stated above, the T3-PA metastatic cell
line has not been evaluated for additional tumorigenic cap-
abilities.) The T4-PA cells were more metastatic than the other cell
lines since the few nude mice injected developed lesions in a
broader variety of target tissues (Table 2). Although only a few
mice were injected with either cell line, the T4-PA cell line appears
to more likely have undergone a cellular change allowing it to
escape the circulation more easily and invade a broader variety of
distant tissues (Table 2). Representative photomicrographs of all
the cell types are shown in Fig. 2. Further studies are needed to
conﬁrm these initial apparent tumorigenic differences among
these new cell lines that have progressed in series from a common
origin, the GhrasT-NIH/3T3 cells.
3.9. Location of the ras oncogene in the cell lines by PCR
The presence of the human HRAS oncogene was conﬁrmed by
PCR ampliﬁcation using human speciﬁc HRAS primers that do not
amplify the mouse h-ras proto-oncogene, but do amplify regions
of the human proto-oncogene or oncogene (Fig. 3). To determine if
any tumors arose from spontaneous tumors and therefore were
unrelated to the original GhrasT-NIH/3T3 cell line, four primers for
two PCR assays were designed. This spontaneous occurrence was a
possibility, since one spontaneous tumor did occur in the nude
NIH Swiss mouse colony used to generate nude mice for these
studies. Although the coding portion of the c-H-ras-1 gene in
mouse, human, rat and hamster are extremely similar, there are
signiﬁcant differences among these species in their gene's three
introns [25]. The two PCR primer sets described in the material
and methods were able to successfully discriminate between
mouse and human h-ras sequences. The human primers only de-
tect either the human c-H-ras-1 oncogene or the human normal
proto-oncogene (yielding a 1152 bp PCR product from the 3′ non-
translated region). The mouse primers detect only the mouse h-ras
proto-oncogene (the M. musculus gene for C-H-Ras; yielding a
216 bp PCR product coded in the third intron) present in the NIH/
Swiss genome. The normal mouse ras proto-oncogene should only
be present in the mouse cells, including the mouse cell lines and
mouse liver (control). The human H-ras oncogene should only be
in the GhrasT-NIH/Swiss, T1-A, T2-A, T3-HA and T4-PA cell lines as
well as in human placenta DNA (control) but not in the NIH/Swiss
cells or the NIH/3T3 cell line. This pattern of ras detection was
observed in all lines tested (Fig. 3). The PCR results conﬁrm that
the tumors used to propagate the T1-A, T2-A, T3-HA and T4-PA
cell lines in this tumorigenic model were all derived from the
GhrasT-NIH/3T3 cells and not produced simply by random spon-
taneous tumorigenic events, since the human ras oncogene was
still found in the T2-A and T4-PA mouse cell lines. The presence of
human ras in the T1-C and T3-PA cell lines remains untested since
they are not direct precursors to the T2-A or T4-PA cell lines. They
are presumed to contain the human ras oncogene as well since
there is no obvious occurrence of spontaneous tumors in these
studies.
3.10. Growth rates of each cell line
The growth rates (Fig. 4) for each cell line were determined
from photomicrographs taken at different times of six pre-speci-
ﬁed 22 mm2 grids on gridded plates in each experiment (Fig. 4
inset). The doubling time in log phase growth for NIH/3T3 cells
determined by this new method compared well with values ob-
tained from counting cells by hemocytometry in which cells were
harvested from multi-well plates on a daily basis to obtain dou-
bling times (Table 3 and Fig. 4). An advantage of this new method
include the ability to quantify the cell growth within the same six
DNA added NIH/3T3 T2-A T4-PA Mouse Liver Human  Placenta 
HRAS Primer Set M H M H M H M H M H
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Human 1152 bp
Mouse 216 bp 
Fig. 3. Detection of mouse and human ras genes by PCR analysis. Agarose gel electrophoresis of mouse and human HRAS PCR products: total DNAwas isolated from NIH/3T3,
T-2A and T4-PA cell lines and mouse liver. Human placenta DNA was purchased commercially. PCR Reactions were performed using human primer set (HN-3630 with HT-
4781) or mouse primer set (MN-1121 with MT-1336) on each DNA sample. Products were analyzed by agarose gel electrophoresis and portions of each gel photograph are
shown at the human 1152 bp and mouse 216 bp size regions detected in ethidium bromide stained slab gels. Lanes 1, 2, 5, 6, 9, 10, 13, 14, 17 and 18 show results from the
mouse primer set and lanes 3, 4, 7, 8, 11, 12, 15, 16, 19 and 20 show results from the human primer set. No products appeared in controls with each primer set without added
DNA (not shown). M¼primer set, H¼Human primer set.
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ment. This is accomplished with fewer dishes plated initially and
eliminates variations in cell counts inherent in recovering an un-
equal percentage of cells from replicate dishes in the preparations
required to use the hemocytometer. Moreover the cells can be
recounted from the photomicrographic records if necessary. The
average doubling time of the transformed cells GhrasT-NIH/3T3
(17 h), T1A (17.5 h), T2A (15.5 h), T3-HA (17.5 h) and T4-PA (18.5 h)
was 17.2 (st.dev. 1.1 h). The doubling times for the NIH Swiss pri-
mary cells and NIH/3T3 cells were 22 h each. Therefore the aver-
age doubling time for the transformed cell lines was signiﬁcantly
shorter than that of the non-transformed cell types (P¼0.006). In
cell growth inhibitor studies ethanol or DMSO needed to solubilize
test compounds can be as high as 0.1% in control cultures without
signiﬁcant growth rate effects compared to growth rates in media
without added ethanol or DMSO. (D.B. Ray, pers. comm.).4. Summary
The cell lines developed and characterized in these studiesTable 3
Doubling times for normal and transformed cells from photomicrographs or
hemocytometer.
Graph
day
zero
Cells Doubling
times in
hoursa
Growth
curve ex-
ponential ﬁt
R2
R2 in
log
phase
data
pts
used
Counting method
0 NIH Swiss 22 0.99783 0,1,2,3 Gridded plateb
1 NIH/3T3 22 1,2 Gridded plate
1 NIH/3T3 22 0.99966 1,2,3 Hemocytometer-1c
1 NIH/3T3 22 1,4 Hemocytometer-2
Average for
normal
22
2 GhrasT-NIH/
3T3
17 0.99402 1,2,5 Gridded plate
3 T1-A 17.5 0.99939 3,4,5 Gridded plate
4 T2-A 15.5 4,7 Gridded plate
5 T3-HA 17.5 0.99956 5,6,7 Gridded plate
6 T4-PA 18.5 0.99997 7,9,11 Gridded plate
Average for
transformed
17.2
Std dev 1.095
P value¼0.0006 between average normal cell and average transformed cell dou-
bling.
aCells were grown and photographed or harvested at deﬁned time intervals to
obtain cell counts in log phase.
bData was obtained from photographs of six grids on gridded plates.
cCells were harvested daily from plates and live cells, showing trypan blue exclu-
sion, were counted in 4 chambers of a hemocytometer.have variable abilities to produce primary tumors and metastatic
lesions. Most noticeable is the difference in the rate and occur-
rence between the tumorigenic capacity of the GrasT-NIH/Swiss
cells and the T1-A cells. When the GhrasT-NIH/3T3 cells estab-
lished the tumors that produced growth of the T1-A and T1-C
tumors, cellular adaptation and tumorigenic capacity increased
dramatically in both T1-A and T1-C cell lines. This could be ex-
plained by exposure to the microenvironment in vivo as well as
haplotype genomic changes and associated gene expression
changes leading to a more aggressive tumorigenic capacity. This
type of change may be similar to the epithelial to mesenchymal
transition (EMT) known to occur in epithelial cancer cell metas-
tasis. In fact, micro array studies comparing RNA levels in the NIH
Swiss embryonic cells to those in these T4-PA cells indicate several
key genes are signiﬁcantly up- or down-regulated which are si-
milar to the changes seen in the EMT transitions in breast cancer
cell metastasis (A. W. Sodergren, pers. comm.). The other down
stream cells in this tumor progression model show some inter-
esting properties. The T2-A cells apparently are more able to me-
tabolize to more sites than the T3-HA cells. The T4-PA cells seem to
be better adapted to producing metastatic lesions at more nu-
merous sites than the T3-HA cells (Table 2). Whether these1
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NIH Swiss
NIH/3T3
NIH/3T3 (hemo -1)
NIH/3T3 (hemo -2)
GhrasT-NIH/3T3
T1-A
T2-A
T3-HA
T4-PA
Fig. 4. Using a gridded plate method to determine growth rates for seven cell
types. Each cell type was plated, allowed to grow at least one day and fresh media
was added. Photomicrographs were recorded at 100X of 6 predetermined
22 mm2 grids on each plate at the various time intervals indicated. A depiction of
selecting random grids for a plate is illustrated in the Fig. 4 insert. The average
number of cells in the 6 grids counted in the plate for each cell type each day was
determined along with a standard deviation. Relative growth fold increase was
determined by normalizing each average cell count to the cell count average of the
earliest time point shown in the semi-log graph. To plot all the data on the same
graph, the ﬁrst time point for each cell type was displaced by a one-day on this
graph. The graph for each cell type includes some portion of the log phase of
growth fromwhich the doubling times were determined as listed in Table 3. The R2
value for each growth curve was determined when possible. Doubling times were
determined from each curve and compared, in the case of the NIH/3T3 cells, to the
doubling times determined from two experiments using the standard hemocyt-
ometer method of counting viable cells harvested each day from 4 multiple plates.
Six random grids marked on the bottom of a 60 mm diameter plate with 22 mm2
grids is depicted here and grids are not shown to scale.
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studies with a larger group of animals. WGS, SKY, transcriptome
and proteome analysis along with other phenotypic studies should
provide a more complete picture of how some cells in each cell
line progressed to a highly metastatic state.
Current studies of transformation and tumor progression often
use the primary NIH Swiss embryonic cells and/or the NIH/3T3 cell
line (ATCC-1658) paired with the EJ-6-2-Bam-6a cell line (ATCC-
1888TM) or other cells derived from NIH/3T3 cells transfected with
the pT24-C3 plasmid (ATCC 41000TM) as a model to evaluate the
myriad effects of various treatments on cells progressing from
normal to pre-malignant to malignant and even metastatic po-
tential. The EJ-6-2-Bam-6a cell line and NIH/3T3 cells cell lines are
readily available for investigators throughout the world from the
ATCC repository and have been used for over 4 decades to evaluate
the effects of H-ras-dependent transformation and related che-
motherapeutic, gene knockout or knockdown protocols. Since the
original transfection to create the EJ-6-2-Bam-6a cell line involved
a transfer of the BamHI fragment of the EJ-6-2-Bam-6a, transfec-
tion into a unique site or sites within one cell, it may only re-
present one set of oncogene integration events that led to a
transformed cell. The development of other models such as the
one described here using the T24-Ha-ras1 oncogene DNA at a
different time to transfect a second NIH/3T3 cell to produce the
GhrasT-NIH/3T3 cell line offers the opportunity to compare mo-
lecular outcomes that led to different but similar transformations
of the same NIH/3T3 cell line. DNA and transcriptome sequencing
studies, protein expression studies in combination with Spectral
karyotyping (SKY) comparing the EJ-6-2-Bam-6a and GhrasT-NIH/
3T3 cell lines along with the T1-A, T2-A, T3-HA and T4-PA cells
would be helpful to elucidate the role of the microenvironment
inﬂuences along with the transcriptome and chromosomal chan-
ges that occur to cause tumorigenic and metastatic capabilities.
Since ras oncogene changes or their effects are known to occur in a
large percentage of spontaneous human malignancies, this model
system may also be helpful in evaluating new strategies to repair
or overcome ras oncogene dependent mechanisms to control
cancer cell growth and metastasis.
This ras-transformed NIH/3T3 tumorigenic progression model
may also be useful for studies of transcriptional changes and sto-
chastic chromosomal rearrangements in a series of cells known to
be derived in a series of events beginning with a single char-
acterized origin. The progression model described should prove
very useful since each cell line is related to the preceding cell and
gives rise to subsequent cells in this series as these cells display
progressively increasing tumorigenic potential.
Although quite abnormal, the HeLa cell line genome is rela-
tively stable since apparently few new mutations have occurred
after early passaging [1]. Thus, this series of mouse cell lines may
be relatively stable once they have been passaged a few times.
Their availability to study multiple single cells in vitro and/or
in vivo makes them an attractive model to “snap-shoot” the pro-
gressive stages represented by each cell line in this series. This cell
model and other models will help test the models proposed by
others to explain how NCAAs lead to cancer progression [9], the
relationship between stress, chromosome fragmentation, sto-
chastic genome chaos [18], the apparent random interplay of
genomic step wise progress, punctuated (chromoplexy) progres-
sion and single catastrophic events [2] and to aid in unraveling the
correlation between changes in karyotype and phenotype that
occurs in the macroevolution of carcinogenesis and its effect on
tumor behavior [33].
To our knowledge, no other series of HRAS transformed cells
involving this many in vitro/in vivo progressions is available. Other
cell lines that are derivatives of the EJ-6-2-Bam-6a cell line have
not been available in a series similar to this new one derived fromthe T24 human bladder carcinoma DNA transfected within the
pT24-C3 plasmid.Acknowledgments
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